Do you find yourself frequently reaching for over-the-counter eye drops to help relieve your gritty, scratchy and irritated ...

Bausch & Lomb is one of the largest vision care companies in the US. Bausch spun off from its former parent company, Bausch Health, in 2022 and it now operates in three segments: vision care, surgical ...

Discover insights from Bausch + Lomb's Q4 2024 earnings call, highlighting 17% annual growth, innovative eye health solutions, and 2025 revenue projections.

Bausch + Lomb saw a broad-based growth across its three core segments. Vision care, its largest, saw revenue rise 9% to $723 million, while surgical increased 13% to $231 million. Pharmaceuticals rose ...

Bausch & Lomb (NYSE:BLCO) fell 5.6% in premarket trading ... and will not result in a transaction at this time." The eye care company said full separation remains the goal, according to the ...

Eye Drops for Red Eyes: LUMIFY significantly reduces redness to help reveal your eyes' natural radiance. From the eye care experts at Bausch and Lomb, LUMIFY works in 1 minute and lasts up to 8 ...

Bausch + Lomb's product portfolio, particularly its prescription Dry Eye Disease (DED) offerings, has been a focal point for investors and analysts. The company's newest DED drug, Miebo, has shown ...

Listen and subscribe to Opening Bid on Apple Podcasts, Spotify, YouTube, or wherever you find your favorite podcasts. After completing $300 billion in healthcare deals over several decades, there is ...

Bausch & Lomb (NYSE:BLCO) fell 5.6% in premarket trading after ending a sales process without finding a buyer. “Taking Bausch + Lomb private with a third-party buyer was one of several options being ...

Can a dry eye practice be profitable? Presented at: Hawaiian Eye 2025; Jan. 18-24, 2025; Koloa, Hawaii. Disclosures: McDonald reports having disclosures for AbbVie, Alcon, Bausch + Lomb ...